EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Thyroid Dysfunction Induced by Pembrolizumab: Five Case Reports

Tingting Zhang, Jing Li, Junru Cai, Xiang Li, Lu Lin

Case Reports in Oncology · 21.05.2026 · 19 (1) · 933-942

DOI: 10.1159/000552474 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 21.05.2026. Verfasst von Tingting Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Heyuan People's Hospital, Heyuan, China. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Although pembrolizumab, as a programmed cell death receptor-1 (PD-1) inhibitor, has revolutionized cancer therapy, it is frequently accompanied by immune-related adverse events. Thyroid dysfunction represents a common irAE, yet its clinical trajectory, optimal management approaches, and long-term outcomes remain incompletely characterized. Case Presentation: We conducted a retrospective analysis of 5 cancer patients who developed thyroid dysfunction following pembrolizumab therapy. All patients ultimately progressed to hypothyroidism, manifesting heterogeneous patterns: biphasic thyroid dysfunction, persistent hypothyroidism, and delayed presentation after treatment cessation. Patients with baseline positivity for thyroid antibodies (thyroglobulin/thyroid peroxidase antibodies) and elevated thyrotropin levels demonstrated higher susceptibility to severe hypothyroidism. Longitudinal follow-up revealed that thyroid function achieved stabilization following early initiation of hormone replacement therapy, whereas delayed intervention was associated with increased requirements for hormone dose titration.

Conclusion

Thyroid dysfunction induced by pembrolizumab is characterized by diverse clinical manifestations and heterogeneous timing of onset. Combination regimens and baseline thyroid status may be significantly associated with its course. Re-treatment risk assessment and dynamic monitoring during therapy should be strengthened in clinical practice as early intervention may improve patient outcomes.

Schlagwörter

Stichwörter der Autor:innen

Immune checkpoint inhibitorPembrolizumabSide effectThyroid dysfunction

Autor:innen und Institutionen

  • Department of Pharmacy, Heyuan People's Hospital, Heyuan, China.
  • Department of Pharmacy, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
  • Department of Pharmacy, Xiangtan Traditional Chinese Medicine Hospital, Xiangtan, China.

Zitieren

APA

Zhang, T., Li, J., Cai, J., Li, X., & Lin, L. (2026). Thyroid Dysfunction Induced by Pembrolizumab: Five Case Reports. Case Reports in Oncology, 19(1), 933-942. https://doi.org/10.1159/000552474

Vancouver

Zhang T, Li J, Cai J, Li X, Lin L. Thyroid Dysfunction Induced by Pembrolizumab: Five Case Reports. Case Reports in Oncology. 2026;19(1):933-942. doi:10.1159/000552474

BibTeX
@article{Zhang2026,
  author = {Zhang, Tingting and Li, Jing and Cai, Junru and Li, Xiang and Lin, Lu},
  title = {Thyroid Dysfunction Induced by Pembrolizumab: Five Case Reports},
  journal = {Case Reports in Oncology},
  year = {2026},
  volume = {19},
  number = {1},
  pages = {933--942},
  doi = {10.1159/000552474}
}
Kostenlos starten →